Send to:

Choose Destination
See comment in PubMed Commons below
Basic Clin Pharmacol Toxicol. 2010 Sep;107(3):724-9. doi: 10.1111/j.1742-7843.2010.00570.x. Epub 2010 Apr 14.

Systemic hyperthermia masks the neuroprotective effects of MK-801, but not rosiglitazone in brain ischaemia.

Author information

  • 1Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.


The use of neuroprotective agents has been under investigation for the treatment of ischaemic brain stroke. In this study, we examined the effects of rosiglitazone and MK-801, two potential neuroprotectants, on thromboembloic focal stroke in hyperthermic rats. The animals were assigned into groups of rosiglitazone, MK-801 and control, all under both normothermic and hyperthermic conditions. A focal ischaemia was induced by injection of preformed clot into the origin of the middle cerebral artery. The animals were assessed by measuring infarct size and brain oedema and also evaluating neurological deficit and seizure activity. Rosiglitazone improved infarct volume and neurological deficit in both normo- (36%) and hyperthermic (63%) animals; but MK-801 only improved normothermic animals. Our results do not support the use of MK-801 in hyperthermic conditions of brain stroke but suggest that rosiglitazone may preserve its efficiency even in hyperthermia.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk